~~<i id='725DC5CE9C'><strike id='725DC5CE9C'><tt id='725DC5CE9C'><pre id='725DC5CE9C'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：knowledge 2025-10-02 04:33:10 Page View：276

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Color Health wants to make cancer screenings convenient
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

JUSTINTALLIS/AFPviaGettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup toge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

AdobeTheterm“raredisease”isbothanaptdescriptorandamisnomer.Individually,eachrarediseaseaffectsarelat